Logo image of HARP

HARPOON THERAPEUTICS INC (HARP) Stock Fundamental Analysis

NASDAQ:HARP - Nasdaq - US41358P2056 - Common Stock - Currency: USD

23.01  +0.02 (+0.09%)

After market: 23 -0.01 (-0.04%)

Fundamental Rating

2

Taking everything into account, HARP scores 2 out of 10 in our fundamental rating. HARP was compared to 566 industry peers in the Biotechnology industry. HARP may be in some trouble as it scores bad on both profitability and health. HARP is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HARP has reported negative net income.
HARP had a negative operating cash flow in the past year.
In the past 5 years HARP always reported negative net income.
In the past 5 years HARP always reported negative operating cash flow.
HARP Yearly Net Income VS EBIT VS OCF VS FCFHARP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 0 -20M -40M -60M -80M -100M

1.2 Ratios

Looking at the Return On Assets, with a value of -64.08%, HARP is doing worse than 62.79% of the companies in the same industry.
The Return On Equity of HARP (-677.78%) is worse than 83.16% of its industry peers.
Industry RankSector Rank
ROA -64.08%
ROE -677.78%
ROIC N/A
ROA(3y)-65.35%
ROA(5y)-50.84%
ROE(3y)-515.97%
ROE(5y)-328.58%
ROIC(3y)N/A
ROIC(5y)N/A
HARP Yearly ROA, ROE, ROICHARP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -200 -400 -600 -800 -1K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for HARP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HARP Yearly Profit, Operating, Gross MarginsHARP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

HARP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HARP has been increased compared to 1 year ago.
There is no outstanding debt for HARP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
HARP Yearly Shares OutstandingHARP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 1M 2M 3M
HARP Yearly Total Debt VS Total AssetsHARP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -5.25, we must say that HARP is in the distress zone and has some risk of bankruptcy.
HARP has a Altman-Z score of -5.25. This is in the lower half of the industry: HARP underperforms 65.66% of its industry peers.
A Debt/Equity ratio of 1.96 is on the high side and indicates that HARP has dependencies on debt financing.
HARP has a Debt to Equity ratio of 1.96. This is amonst the worse of the industry: HARP underperforms 82.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.96
Debt/FCF N/A
Altman-Z -5.25
ROIC/WACCN/A
WACC8.93%
HARP Yearly LT Debt VS Equity VS FCFHARP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 50M -50M -100M

2.3 Liquidity

HARP has a Current Ratio of 1.90. This is a normal value and indicates that HARP is financially healthy and should not expect problems in meeting its short term obligations.
With a Current ratio value of 1.90, HARP is not doing good in the industry: 79.46% of the companies in the same industry are doing better.
HARP has a Quick Ratio of 1.90. This is a normal value and indicates that HARP is financially healthy and should not expect problems in meeting its short term obligations.
HARP has a worse Quick ratio (1.90) than 77.61% of its industry peers.
Industry RankSector Rank
Current Ratio 1.9
Quick Ratio 1.9
HARP Yearly Current Assets VS Current LiabilitesHARP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M

More info and screens

6

3. Growth

3.1 Past

HARP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 44.06%, which is quite impressive.
The Revenue has grown by 16.11% in the past year. This is quite good.
Measured over the past years, HARP shows a very strong growth in Revenue. The Revenue has been growing by 114.07% on average per year.
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
Revenue 1Y (TTM)16.11%
Revenue growth 3Y76.76%
Revenue growth 5Y114.07%
Sales Q2Q%-67.33%

3.2 Future

The Earnings Per Share is expected to grow by 14.65% on average over the next years. This is quite good.
HARP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 23.74% yearly.
EPS Next Y90.06%
EPS Next 2Y34.83%
EPS Next 3Y21.93%
EPS Next 5Y14.65%
Revenue Next Year8.24%
Revenue Next 2Y-23.33%
Revenue Next 3Y-16.53%
Revenue Next 5Y23.74%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
HARP Yearly Revenue VS EstimatesHARP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M
HARP Yearly EPS VS EstimatesHARP Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

HARP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for HARP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HARP Price Earnings VS Forward Price EarningsHARP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HARP Per share dataHARP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as HARP's earnings are expected to grow with 21.93% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.83%
EPS Next 3Y21.93%

More info and screens

0

5. Dividend

5.1 Amount

HARP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HARPOON THERAPEUTICS INC

NASDAQ:HARP (3/8/2024, 8:11:33 PM)

After market: 23 -0.01 (-0.04%)

23.01

+0.02 (+0.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2023-11-09/amc
Earnings (Next)03-25 2024-03-25/amc
Inst Owners16.15%
Inst Owner Change0%
Ins Owners20%
Ins Owner Change0%
Market Cap492.41M
Analysts72
Price Target24.14 (4.91%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)97.26%
Min EPS beat(2)85.9%
Max EPS beat(2)108.62%
EPS beat(4)3
Avg EPS beat(4)49.93%
Min EPS beat(4)-15.5%
Max EPS beat(4)108.62%
EPS beat(8)5
Avg EPS beat(8)22.83%
EPS beat(12)8
Avg EPS beat(12)17.05%
EPS beat(16)8
Avg EPS beat(16)10.37%
Revenue beat(2)2
Avg Revenue beat(2)144.15%
Min Revenue beat(2)3.22%
Max Revenue beat(2)285.07%
Revenue beat(4)3
Avg Revenue beat(4)80.03%
Min Revenue beat(4)-43.07%
Max Revenue beat(4)285.07%
Revenue beat(8)5
Avg Revenue beat(8)51.6%
Revenue beat(12)7
Avg Revenue beat(12)36.71%
Revenue beat(16)7
Avg Revenue beat(16)16.33%
PT rev (1m)5.58%
PT rev (3m)57.81%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.01%
EPS NY rev (1m)0%
EPS NY rev (3m)25.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)6.92%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.24%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.19
P/FCF N/A
P/OCF N/A
P/B 107.05
P/tB 107.05
EV/EBITDA N/A
EPS(TTM)-8.76
EYN/A
EPS(NY)-3.73
Fwd EYN/A
FCF(TTM)-3.25
FCFYN/A
OCF(TTM)-3.24
OCFYN/A
SpS1.74
BVpS0.21
TBVpS0.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -64.08%
ROE -677.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-65.35%
ROA(5y)-50.84%
ROE(3y)-515.97%
ROE(5y)-328.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.78
Health
Industry RankSector Rank
Debt/Equity 1.96
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.15%
Cap/Sales 0.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.9
Quick Ratio 1.9
Altman-Z -5.25
F-Score4
WACC8.93%
ROIC/WACCN/A
Cap/Depr(3y)17.36%
Cap/Depr(5y)109.27%
Cap/Sales(3y)1.81%
Cap/Sales(5y)16.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)44.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%86.86%
EPS Next Y90.06%
EPS Next 2Y34.83%
EPS Next 3Y21.93%
EPS Next 5Y14.65%
Revenue 1Y (TTM)16.11%
Revenue growth 3Y76.76%
Revenue growth 5Y114.07%
Sales Q2Q%-67.33%
Revenue Next Year8.24%
Revenue Next 2Y-23.33%
Revenue Next 3Y-16.53%
Revenue Next 5Y23.74%
EBIT growth 1Y47.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year45.99%
EBIT Next 3Y-5.42%
EBIT Next 5YN/A
FCF growth 1Y42.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y42.42%
OCF growth 3YN/A
OCF growth 5YN/A